tapebrief
BAX · Q2 2025
BAX · Q4 2025

BAX · Q3 2025 Earnings

Bearish

Baxter International

Reported October 30, 2025

30-second summary

Baxter's first quarter under new CEO Andrew Hider was a full reset: FY2025 operational sales growth guidance cut to 1–2% from 3–4%, adjusted EPS to $2.35–$2.40 from $2.42–$2.52, operating margin to 14.5–15% from 15–16%, and the quarterly dividend slashed to one cent to free up $300M+ of annual cash flow. The Novum IQ LVP hold now extends beyond year-end with no resolution timeline, and Q4 operational sales are guided to decline ~2% YoY — the first quarter of guided negative growth. Management's three-times net leverage target slipped a full year to end of 2026.

Headline numbers

EPS

Q3 FY2025

$0.69

Revenue

Q3 FY2025

$2.83B

+5.0% YoY

Gross margin

Q3 FY2025

33.5%

Operating margin

Q3 FY2025

6.1%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$2.83B+5.0%$2.81B+0.9%
EPS$0.69—$0.59+16.9%
Gross margin33.5%—35.3%-180bps
Operating margin6.1%—6.8%-70bps

Guidance

Baxter substantially lowered FY2025 guidance across EPS, sales growth, margins, and tax rate due to infusion pump production holds and prolonged fluid conservation; Q4 forecast signals further deterioration into year-end.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Adjusted EPS (non-GAAP)Q3 FY2025$0.58 to $0.62$0.69+$0.07-0.11 above guideBeat
Reported Sales GrowthQ3 FY20256% to 7%5%-1-2 pts below guideMissed
Operational Sales GrowthQ3 FY20253% to 4%2%-1-2 pts below guideBeat

New guidance

MetricPeriodGuideYoY
Adjusted EPS (non-GAAP)Q4 FY2025$0.52 to $0.57—
Reported Sales GrowthQ4 FY2025approximately 2%—
Operational Sales GrowthQ4 FY2025decline approximately 2%—

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Adjusted EPS (non-GAAP)
FY2025
$2.42 to $2.52$2.35 to $2.40-$0.02 to -$0.12 (midpoint -$0.10)Lowered
Reported Sales Growth
FY2025
6% to 7%4% to 5%-1-3 ptsLowered
Operational Sales Growth
FY2025
3% to 4%1% to 2%-1-3 ptsLowered
Adjusted Operating Margin
FY2025
15% to 16%14.5% to 15%-50 to -150 bpsLowered
Tax Rate
FY2025
approximately 18% to 18.5%approximately 15%-300 to -350 bpsLowered

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Medical Products & Therapies$1.329B-1.0%
Healthcare Systems & Technologies$0.773B+3.0%
Pharmaceuticals$0.632B+7.0%
Infusion Therapies & Technologies Revenue$1,023 million—
Advanced Surgery Revenue$306 million—
Care & Connectivity Solutions Revenue$473 million—
Drug Compounding Revenue$299 million—

Other KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
U.S. Sales$1.544B+3.0%
International Sales$1.291B+8.0%
Adjusted Operating Income$423 million—
Adjusted Diluted EPS from Continuing Operations$0.69—
Operational Sales Growth2%—
Adjusted Gross Margin39.4%—

Management tone

Q1 "execution on track" → Q2 "prudent downside" → Q3 "reset and stabilize."

Management language moved from "prudent" to outright dissatisfaction. Last quarter the CFO framed the walk-down as capturing downside risks; this quarter the new CEO opened with: "We are not satisfied with our current performance. There is a recognition that challenges must be met head on with both immediate actions as well as real long-term solutions." This is not a tonal adjustment — it is a new posture of management openly grading itself as failing, and it telegraphs more tough actions ahead.

Novum LVP went from "goal to resume by year-end" to "beyond year-end with no timeline." In Q2 management framed Novum as a Q4-resolution scenario; this quarter the CFO said: "While we're disappointed that we expect the current hold to remain in place beyond year end, we are working tirelessly to evaluate and test potential corrections to fully resolve the flow rate issues." The shift matters because Baxter also conceded customers are now initiating returns and exchanges to Spectrum IQ — the hold is converting into structural customer attrition, not just a deferred revenue event.

IV conservation reframed from "post-hurricane recovery" to "structural behavior change." Through Q1 and Q2 management held the line that hospital fluid conservation was a Helene aftershock that would normalize. This quarter the CFO referenced the 2017 IV shortage precedent, which took ~2 years to normalize, and acknowledged conservation "is likely to remain in 2026." The framing has moved from temporary supply-side to permanent demand-side, which is a categorically different problem.

Capital allocation pivoted from optionality to deleveraging triage. The dividend cut to one cent — freeing $300M+ annually — and the slip of the 3x net leverage target from end-2025 to end-2026 say that management no longer believes operating cash flow alone can rebuild the balance sheet on the prior timeline. CEO Hider's "higher say-do ratio" line is a direct acknowledgment that prior management overpromised.

Hedging language proliferated. Phrases like "some level of fluid conservation is likely to remain in 2026," "timing and nature of the resolution of the Novum LVP hold is leading some customers to evaluate alternative solutions," and the deferral of every strategic question to a 2026 investor day all read as a management team explicitly buying time.

Recurring themes management leaned on this quarter:

Infusion pump portfolio disruption (Novum IQ LVP hold)Post-hurricane fluid conservation impacting IV Solutions demandBalance sheet deleveraging and dividend reductionBusiness stabilization required in ITT and injectables divisionsOperational execution and culture change (GPS system)Margin pressure from tariffs, supply costs, and lower volumes

Risks management surfaced:

Novum IQ LVP field action hold extending beyond year-end with uncertain resolution timelineContinued softness in U.S. hospital IV solutions and fluid conservation persisting into 2026Tariff impact estimated at $40 million for 2025Macroeconomic uncertainty affecting capital spending despite current strengthCustomer attrition from Novum IQ to alternative solutions during hold period

Q&A highlights

Robert Marcus · J.P. Morgan

New CEO's vision for Baxter after two months, including capital allocation strategy and business health assessment. Follow-up on 2026 growth prospects given Q4 underperformance and guidance reset.

CEO emphasized three focus areas: stabilizing the business and execution, strengthening balance sheet, and driving continuous improvement culture (GPS system). Expects to outpace markets and anticipates growth in 2026, with detailed strategy to be shared at investor day. No specific 2026 guidance provided.

Three strategic pillars: stabilization/execution, balance sheet strengthening, continuous improvement cultureGPS (Growth and Performance System) launchedInvestor day planned for 2026CEO visiting customers frequently

David Roman · Goldman Sachs

Company identity and strategic positioning (MedTech vs. diversified manufacturer). Follow-up on mix headwinds from lower-margin compounding growth versus higher-margin segments and implications for 2025-2026 P&L.

CEO deferred detailed strategic positioning to 2026 investor day, emphasizing capital allocation framework. CFO detailed mix challenges: compounding growing but lower-margin; advanced surgery (MPT) strong; pharma injectables soft due to IV protocol shifts and pre-mixed product weakness; Novum field actions pressuring infusion pumps.

Capital allocation as success frameworkAdvanced surgery/MPT showing strong positive mixCompounding growth outpaced by margin dilution concernsInjectables facing softness in U.S. pre-mixed products

Travis Steed · BofA Securities

Novum timing and resolution path (redesign vs. FDA resubmission). Customer impact and contribution to guidance reduction. M&A appetite and timing given balance sheet constraints.

Novum hold ongoing to develop field action corrections; unable to commit to specific timeline, expect resolution beyond 2025. Some customers evaluating alternatives, initiating returns/exchanges to Spectrum. CEO indicated balance sheet deleveraging is priority before M&A, though will pursue tuck-in/hold-and-build opportunities. Strong product launch (Connect360 in FLC) underway.

Novum resolution expected beyond 2025Customer exchange activity to Spectrum IQ underwayWorking with regulators on field actionsBalance sheet deleveraging prioritized over M&A

Joanne Winch · Citi

IV fluid conservation persistence post-Hurricane Helene (normalization vs. recovery narrative). Hospital capex spending patterns and political/regulatory uncertainty impact.

CFO indicated fluid conservation is ongoing buying pattern behavior, not just post-hurricane recovery; recovery expected but at slower pace than anticipated. Referenced 2017 similar incident took ~2 years to normalize. Hospital capex order book robust with 30% YoY growth; no hesitancy observed yet despite Washington uncertainty.

IV demand remains below post-hurricane baselineCustomer buying patterns reflect sustained conservationRecovery timeline: potentially 1-2 years (per 2017 precedent)Hospital HST order book up ~30% YoY

Matt Mixkit · Barclays

IV demand weakness reconciliation: strong surgical/procedure volumes elsewhere in medtech suggest either competitive loss, procedure mix shift to outpatient, or other factors explaining IV solution softness.

CFO reiterated customer communication on continued fluid conservation focus, referencing external articles with hospital CEO commentary. Emphasized team actively working on utilization improvement and reinforcing clinical value. Recovery in guidance reflects best expectations; no indication of competitive losses or product availability issues.

Hospital conservation behavior documented in external mediaProduct availability not the constraintTeams focusing on utilization improvement and clinical value reinforcementRecovery timeline uncertain and below prior expectations

Answers to last quarter's watch list

Novum LVP shipment resumption — Did not happen. Management now expects the hold to "remain in place beyond year end" with no resolution timeline, and customers are initiating returns/exchanges to Spectrum IQ. The low-end FY scenario from Q2 is now the base case, and Q4 has indeed walked down further. Status: Resolved negatively
IV conservation trajectory — Worsened. Management reframed conservation as structural behavior change persisting into 2026, and cited the 2017 ~2-year normalization precedent. Q4 operational growth guided to -2% reflects no recovery in H2. Status: Resolved negatively
U.S. injectables and IV-push utilization — The hurricane-induced protocol shift is now management's working assumption — IV-push displacement of pre-mixed product is being treated as durable, not transient. Pharma's headline +7% growth masks continuing injectables softness. Status: Resolved negatively
Adj. operating margin — FY guide cut from 15–16% to 14.5–15%, abandoning the H2 expansion thesis off the Q2 base. Operating margin guidance was cut 50–100bps. Status: Resolved negatively
Tariff assumption — Net tariff impact held at ~$40M for 2025; not reversed. The FY tax rate cut to ~15% from 18–18.5% is the unexpected EPS-supportive item, but management did not tie it to operational improvement — likely discrete or geographic mix items. Status: Resolved positively (narrow scope: tariff line held)

What to watch into next quarter

Novum LVP resolution timeline — watch for any specific FDA submission date, corrective action timeline, or customer retention metric; absence of any of these on the Q4 call extends the customer-attrition window into 2026 and threatens FY2026 MPT growth.

Q4 operational growth vs. -2% guide — a Q4 print at or below -2% confirms structural deterioration; a beat (e.g. flat or slightly positive) would suggest the -2% was conservatism for the new CEO's first reset.

MPT segment growth in Q4 — track whether MPT goes deeper than the -1% printed in Q3; sustained MPT contraction forces the question of whether the segment can grow at all in 2026.

Adj. operating margin trajectory — Q4 implied margin from the new FY guide sits near or below Q3 levels; watch for any commentary on cost actions, structural margin pressure, or Vantive MSA roll-off.

Dividend cut cash deployment — the $300M+ freed by the dividend cut should accelerate debt paydown; watch net debt and the 3x leverage target trajectory against the new end-2026 deadline.

Investor day timing and content — Hider deferred every strategic question to a 2026 investor day; the date itself and any preview of portfolio rationalization (divestitures, M&A appetite) will set the 2026 narrative.

Sources

  1. Baxter International Q3 2025 press release / 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/10456/000162828025047311/bax-20250930xex991.htm
  2. Baxter International Q3 2025 earnings call prepared remarks and Q&A
  3. Tapebrief Q2 FY2025 BAX coverage (prior watch list and guide baseline)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.